Roflumilast: a review of its use in the treatment of COPD by Wedzicha, J et al.
© 2016 Wedzicha et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of COPD 2016:11 81–90
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
81
R e v I e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S89849
Roflumilast: a review of its use in the treatment 
of COPD
Jadwiga A Wedzicha1
Peter MA Calverley2
Klaus F Rabe3,4
1Airways Disease Section, National 
Heart and Lung Institute, Imperial 
College London, London, 2Institute 
of Ageing and Chronic Disease, 
University of Liverpool, Liverpool, UK; 
3Department of Internal Medicine, 
Christian-Albrechts University, Kiel, 
4Department of Pulmonary Medicine 
and Medical Director, LungenClinic 
Grosshansdorf, Airway Research 
Centre North, German Centre 
for Lung Research, Grosshansdorf, 
Germany
Abstract: COPD is a progressive condition involving chronic inflammation and parenchymal 
destruction with resulting airflow limitation. COPD is associated with worsening airflow limita-
tion over time and increased frequency of COPD exacerbations, leading to increased mortality 
and morbidity. The effects of COPD extend beyond the lungs, as multiple comorbidities may 
occur with COPD, including cardiovascular disease, diabetes mellitus, osteoporosis, depres-
sion, and pneumonia. COPD exacerbations are associated with a rapid worsening of baseline 
symptoms that requires prompt management and may necessitate hospitalization in the case of a 
severe episode. Patients with COPD exacerbations require urgent management of symptoms to 
prevent further worsening, and preventative steps may be taken to help reduce the number and 
frequency of future exacerbations. Roflumilast is a potent and selective inhibitor of the enzyme 
phosphodiesterase-4 that targets the systemic inflammation associated with COPD. Roflumilast 
has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the 
expression of cell surface markers and inhibition of apoptosis. Several clinical trials evaluating 
roflumilast in the treatment of COPD have demonstrated significant improvements from baseline 
versus placebo in lung function, including increases in mean pre- and postbronchodilator forced 
expiratory volume in 1 second and forced vital capacity. Data suggest that roflumilast reduces 
moderate to severe exacerbations with the benefit most well established in patients with severe 
disease. Given this evidence, roflumilast, as part of a combination regimen with long-acting 
bronchodilators, appears to be a reasonable treatment option for patients with severe to very 
severe COPD associated with chronic bronchitis and a history of exacerbations.
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Introduction
COPD is a progressive condition that usually leads to a steady decline in lung function, 
increased symptoms, and recurrent and worsening exacerbations.1 The progressive 
airflow limitation that characterizes COPD is a result of chronic airway inflammation 
in response to the inhalation of noxious stimuli and resulting parenchymal destruction.2 
Many systemic inflammatory markers have been associated with COPD health status 
and its extrapulmonary effects.1,3,4 Inflammatory cells, tissue swelling, and accumu-
lated mucus directly obstruct airways, but also activate innate repair mechanisms that 
remodel and thicken airway walls over time, leading to parenchymal destruction.5,6 
Parenchymal destruction leads to further decreased gas transfer and increased air 
trapping. Overall, the combined pathological defects of COPD translate to symptoms 
of breathlessness, coughing, and variable sputum production that greatly impact a 
patient’s quality of life.2
COPD is associated with an approximate 3.5-fold increase in the risk of death and 
is linked to multiple comorbidities, including hypertension, heart failure, ischemic 
heart disease, diabetes mellitus, myocardial infarction, osteoporosis, depression, 
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and pneumonia.7–9 Exposure to viral or bacterial pathogens 
or inhalation of pollutants may be sufficient to precipitate 
a COPD exacerbation, defined as an acute worsening of a 
patient’s baseline symptoms.10–12 COPD exacerbations are 
accompanied by marked increases in systemic inflamma-
tory mediators,13–16 decreased quality of life,17 and further 
elevated risk of morbidity and mortality with each succes-
sive exacerbation compared with baseline disease.18–20 Some 
patients with COPD may be more prone to frequent COPD 
exacerbations (Figure 1) and thus present a greater thera-
peutic challenge.10 This recognition is underscored in the 
guidelines for the management of COPD, which emphasize 
the importance of minimizing the impact of current exac-
erbations and preventing the development of subsequent 
exacerbations.21,22
The purpose of this review is to highlight the pharmacology, 
clinical efficacy, tolerability, and place in therapy of roflumi-
last for the treatment of patients with COPD.
Pharmacology
Pharmacodynamics
Roflumilast, a potent and selective inhibitor of phospho-
diesterase-4 (PDE4), is indicated for treatment to reduce 
the risk of COPD exacerbations in patients with severe 
COPD associated with chronic bronchitis and a history of 
exacerbations.23,24 Selective inhibition of PDE4 inhibits the 
hydrolysis of cyclic adenosine monophosphate (cAMP) in 
inflammatory cells.25 Increased intracellular cAMP results in a 
wide range of anti-inflammatory effects, including decreased 
release of inflammatory mediators in neutrophils, decreased 
release of cytokines,24 decreased expression of cell surface 
markers in many cell types, and decreased apoptosis. The 
suppression of inflammatory mediators and cytokines usually 
translates into benefits for patients with COPD exacerbations 
who often have elevated markers of inflammation compared 
to patients with baseline disease.26 Roflumilast also reduces 
allergen-induced inflammation27 and has been shown to sta-
bilize lipopolysaccharide-induced systemic inflammation.28
Pharmacokinetics
Roflumilast is available in a once-daily oral dosage form (500 
µg tablets) with a bioavailability of approximately 80%.23 
Maximum plasma concentrations of roflumilast are achieved 
in ~1 hour (range: 0.5–2 hours) after a single dose, and 
maximum concentrations of the active N-oxide metabolite 
are achieved in ~8 hours (range: 4–13 hours). Roflumilast 
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Figure 1 Schematic of the frequent exacerbator phenotype.
Notes: Reproduced from BioMed Central. © 2013 Wedzicha et al; licensee BioMed Central Ltd. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact 
of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. Creative Commons license and disclaimer available from: http://
creativecommons.org/licenses/by/4.0/legalcode.10
Abbreviations: CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; IL-6, interleukin-6.
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and its active metabolite are both highly protein bound in 
plasma ($97%). Metabolism occurs by Phase I cytochrome 
P450 (CYP) reactions (isoenzymes 1A2 and 3A4) and by 
Phase II conjugation, and the half-life is approximately 
17 hours.23 While roflumilast is three times more potent 
than its metabolite, the metabolite has approximately ten 
times greater exposure (plasma area under the curve) than 
the active drug. Patients with hepatic dysfunction may have 
impaired elimination, although dose adjustments are not 
necessary.29 No dosage adjustments are required for renal 
impairment.23 However, roflumilast should not be coadmin-
istered with strong inhibitors of CYP3A4 or dual inhibitors 
of CYP3A4 and CYP1A2 (eg, erythromycin, ketoconazole, 
fluvoxamine, enoxacin, cimetidine, or rifampicin).23 The 
macrolide azithromycin, which is commonly used in patients 
with COPD, is only a weak inhibitor of CYP3A4 and is 
expected to interact with roflumilast to a much lesser degree 
than erythromycin.30
Clinical efficacy
The clinical efficacy and safety of roflumilast in the treatment 
of COPD has been evaluated in nine Phase III/IV random-
ized double-blind clinical trials, including studies M2-107, 
M2-111, M2-112, M2-124, M2-125, M2-127, M2-128, 
ACROSS (ClinicalTrials.gov identifier: NCT01313494), and 
REACT (Roflumilast in the Prevention of COPD Exacerba-
tions While Taking Appropriate Combination Treatment; 
NCT01329029) (Table 1).31–36 Patients in these studies 
were required to have at least a 10–20-year pack history 
of smoking. Studies M2-111, M2-112, M2-124, M2-125, 
and REACT included only patients with severe to very 
severe airflow limitation as assessed by Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria (ie, 
forced expiratory volume in 1 second [FEV
1
] #50%).31,34–36 
Across all Phase III studies, active treatment with 500 µg of 
roflumilast was associated with improvements from baseline 
in lung function, including increases in mean pre- and post-
bronchodilator FEV
1
 ranging from 39 to 88 mL and from 
45 to 97 mL, respectively, compared with placebo with all 
differences statistically significant (P,0.0001).31–33,35–37 In 
addition, postbronchodilator forced vital capacity increased 
58–114 mL compared with placebo (P,0.05).
While studies M2-111 and M2-112 demonstrated that 
roflumilast was associated with improved lung function in 
patients with severe COPD, neither study demonstrated a 
significant effect on exacerbations, although there was a trend 
toward lower exacerbations for roflumilast in each study.34 
When results from the two trials were pooled, a significant 
reduction (14.3%) in moderate to severe exacerbations was 
observed compared with placebo (P=0.026).34 Post hoc 
analyses identified several subgroups of patients that were 
associated with greater response. In particular, patients receiv-
ing concomitant inhaled corticosteroids (ICSs) or short-acting 
anticholinergics, patients with a history of chronic bronchitis 
with or without emphysema, and patients with elevated cough 
or sputum scores at baseline ($1 average score per day) saw 
significant reductions in the incidence rate of moderate to 
severe COPD exacerbations by 18% to 30%.34
The identified patient groups most responsive to roflu-
milast in the M2-111 and M2-112 studies helped to inform 
the design of the subsequent M2-124 and M2-125 studies. 
These trials included patients with COPD aged .40 years 
with severe airflow limitation, bronchitic symptoms, and a 
history of exacerbations. In these studies, roflumilast was not 
only associated with improvements in lung function, but the 
drug was also associated with a 15% reduction in moderate 
or severe exacerbations (P=0.0278) in study M2-124 and an 
18% reduction in M2-125 (P=0.0035).31 In trials M2-127 and 
M2-128, roflumilast also significantly improved lung function 
when combined with salmeterol (M2-127) and tiotropium 
(M2-128) compared with the use of either agent alone.32
Post hoc analyses of these later trials have evaluated the 
efficacy of roflumilast in select subgroups of patients, for 
example, the efficacy of roflumilast in patients who were 
taking concomitant long-acting β
2
-agonists (LABAs).38 
Moderate to severe exacerbations of COPD were reduced 
by 20.7% in patients taking roflumilast concomitantly with 
a LABA (P=0.001) compared with 14.6% in patients taking 
roflumilast alone (P=0.039) (Figure 2).38 Roflumilast also 
prolonged the time to first (P=0.035 with LABA; P=0.300 
without LABA) and second COPD exacerbations (P=0.018 
with LABA; P=0.049 without LABA).38 Patients who had fre-
quent COPD exacerbations ($2) in the year prior to treatment 
with roflumilast saw the greatest reduction versus placebo in 
the incidence of exacerbations compared with patients who 
had infrequent exacerbations (22.3% versus 16.5%, respec-
tively; 95% confidence interval [CI]: 9%–34%).38
As frequent COPD exacerbations have been associated 
with increased morbidity and mortality, an additional analysis 
looked further into endpoints for the frequent exacerbator 
population of patients. For patients with GOLD severe airway 
limitation of 3, treatment with roflumilast may help to shift 
frequent exacerbator patients at baseline to the more stable 
infrequent exacerbator type.39 After 1 year of treatment, only 
26.4% of patients treated with roflumilast who were frequent 
exacerbators at baseline remained frequent exacerbators 
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compared with 38.9% of patients randomized to placebo 
(P=0.0042).39 An additional analysis of studies M2-124 and 
M2-125 demonstrated that roflumilast reduced the rate of 
severe COPD exacerbations leading to hospitalization com-
pared with placebo (rate ratio [RR] 0.78; 95% CI: 0.62–0.90; 
P=0.044).40
A post hoc analysis of study M2-128 indicated that roflu-
milast shows efficacy in patients with highly symptomatic 
COPD.41 Using the modified Medical Research Council 
questionnaire, which evaluates the severity of breathless-
ness, the efficacy of roflumilast in patients with moderate 
to severe COPD and Grade 2 or higher breathlessness was 
evaluated. Mean pre- and postbronchodilator FEV
1
 increased 
by 79 mL and 78 mL, respectively, compared with placebo 
(P=0.0002).41 Roflumilast was associated with a 45.5% 
reduction in moderate to severe exacerbations compared 
with placebo (P=0.0338).41 The reduction observed in this 
subgroup of patients with highly symptomatic COPD was 
greater than the 27% reduction in exacerbations observed in 
the overall study population.32
The most recent study was REACT, a Phase III/IV 
randomized, double-blind, multicenter study designed to 
investigate whether roflumilast further reduces exacerba-
tions when added to inhaled combination therapy (LABA/
ICS) in patients still suffering from frequent exacerbations.42 
Patients were randomized to receive roflumilast 500 µg or 
placebo once daily in combination with a fixed ICS/LABA 
combination. The rate of moderate to severe COPD exacerba-
tions in the intention-to-treat population (primary endpoint) 
was 13.2% lower in the roflumilast group versus the placebo 
group in the Poisson regression analysis (RR 0.868; 95% 
CI: 0.753–1.002; P=0.0529) and was 14.2% lower in the 
negative binomial regression analysis (RR 0.858; 95% CI: 
0.740–0.995; P=0.0424).35 The benefit was evident irrespec-
tive of concomitant use of long-acting antimuscarinic agents. 
Roflumilast was also superior to placebo for reducing severe 
events (RR 0.757; 95% CI: 0.601–0.952; P=0.0175) and for 
reducing exacerbations requiring hospitalization (RR 0.761; 
95% CI: 0.604–0.960; P=0.0209) (Figure 3).35
Quality of life
In the DACOTA (Daxas for COPD therapy; NCT01285167) 
study, the effects of roflumilast on the quality of life of 
patients with COPD (N=3,597) were investigated in a non-
interventional, real-life cohort study for 6 months.43 Patients 
were divided into frequent and infrequent exacerbator 
subpopulations based on their exacerbation history over the 
12 months leading up to treatment with roflumilast. Clinical 
COPD Questionnaire (CCQ) scores (1-week version) and 
COPD Assessment Test (CAT) scores were used to assess 
improvements in quality of life. The minimal clinically 
important difference thresholds for CCQ and CAT scores 
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demonstrating improvement in quality of life are 0.41 and 
2.0, respectively.44,45 At the end of 12 months, both subpopu-
lations showed significant improvements from baseline in 
mean CCQ scores with roflumilast treatment (P,0.001), 
with greater improvements seen for frequent exacerbators 
compared with infrequent exacerbators (-1.00 versus -0.73, 
respectively; P,0.001).43 Similar results were shown for 
CAT scores, with significant improvements from baseline 
scores observed in both subpopulations (P,0.001) and 
significantly greater improvements in frequent exacerbators 
compared with infrequent exacerbators (-6.62 versus -4.91; 
P,0.001).43 An earlier study also demonstrated that treatment 
with roflumilast improved health-related quality of life as 
assessed by the St George’s Respiratory Questionnaire total 
score.33 In this study, roflumilast showed greater improve-
ment in health-related quality of life than placebo, although 
the difference was not statistically significant.
Cost effectiveness
Both COPD treatment and COPD exacerbations have 
an economic impact on health care systems. The total 
direct costs related to COPD in the USA and Europe are 
53.7 billion dollars ($) (COPD/asthma combined)46 and 
23 billion euros (£), respectively.47 Using claims data from 
the United Kingdom National Health Service, a Markov 
cohort model was developed to evaluate the total costs, 
life-years, and quality-adjusted life-years of COPD exacer-
bations related to different COPD regimens.48 Roflumilast 
was found to be generally cost effective when added on to 
standard-of-care therapy. Roflumilast added on to a regi-
men of tiotropium and salmeterol resulted in an incremental 
cost-effectiveness ratio of £13,764/quality-adjusted life-
year gained. When added on to a regimen of tiotropium 
and salmeterol/fluticasone, the result was £16,566/quality-
adjusted life-year gained.48 Similar findings were observed 
for a cost-effectiveness analysis comparing roflumilast added 
on to tiotropium versus tiotropium alone. Roflumilast was 
found to be cost effective as add-on therapy over a period 
of 5 years ($15,815/quality-adjusted life-year).49 Economic 
analyses of data from the REACT study will provide addi-
tional data on the cost effectiveness of roflumilast when used 
in combination with LABA/ICS.
Figure 3 Mean rate of serious exacerbations or exacerbations leading to hospital admission per patient per year in the REACT study.
Notes: Reprinted from The Lancet, Vol. 385, number 9971, Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations 
in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial, Pages 857–866, 
Copyright (2015), with permission from Elsevier.35
Abbreviation: CI, confidence interval.
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Tolerability
Roflumilast is generally well tolerated with adverse events 
(AEs) consistent with those expected for PDE4 inhibitors. 
Combining the data from several 1-year and 6-month clinical 
trials of roflumilast (N=8,630), the most common AEs were 
gastrointestinal disorders (diarrhea and nausea) and weight 
loss (Table 2).50 Other AEs that occurred with greater fre-
quency compared with placebo were back pain, insomnia, 
and decreased appetite. In another pooled safety analysis that 
included data from 14 intermediate- and long-term placebo-
controlled clinical trials of roflumilast (N=12,054), the 
rates of AEs (67.2% versus 62.8%) and severe AEs (13.5% 
versus 14.2%) were found to be near similar compared 
with placebo.51 Rates of infection (25.9% versus 27.5%), 
pneumonia (1.8% versus 2.0%), and cardiovascular AEs 
(5.2% versus 5.7%) were also similar.51 In the REACT trial, 
AEs were reported by 67% of those receiving roflumilast 
compared with 59% of the placebo group, with serious AEs 
reported in 26% and 30%, respectively. However, there were 
more discontinuations due to AEs among those receiving 
roflumilast (n=82) versus placebo (n=29).35
A common systemic effect of COPD is weight loss, 
which can be seen in patients with severe COPD.21,52 Both 
selective and nonselective PDE inhibitors have been associ-
ated with weight loss,37 which may be related to the effects 
of increased cAMP on signaling pathways that regulate 
lipolysis.53 Weight loss in one pooled analysis was found 
to be 2.14 kg greater with roflumilast treatment compared 
with placebo (P,0.0001).51 The extent of weight loss was 
mostly realized within the first 4 weeks of treatment and 
was shown to occur in patients with greater fat mass. After 
discontinuing roflumilast, patients regained one-half of their 
lost weight within 3 months.51 Animal models suggest that 
PDE4 inhibitors may also increase glucagon-like peptide-1 
levels.54 Glucagon-like peptide-1 receptor agonists are used 
in the treatment of diabetes and are also associated with 
weight loss.55 This may serve as another possible explana-
tion for the weight loss seen in patients with COPD treated 
with roflumilast and could also explain favorable effects 
on glycemic parameters as well as the gastrointestinal AEs 
(nausea and diarrhea) associated with the drug. In a 12-week, 
placebo-controlled trial in patients with newly diagnosed type 
2 diabetes mellitus, roflumilast increased insulin sensitivity 
and was associated with a significantly greater change in gly-
cated hemoglobin than placebo (least-square mean =-0.45%; 
P,0.0001) (Figure 4).56
Cardiovascular safety
Patients diagnosed with COPD are approximately 3 and 3.5 
times more likely to experience a stroke and acute myocardial 
infarction,8 respectively. Thus, the effect of COPD treatment 
on cardiovascular safety is a concern for both clinicians and 
patients. Using the same pooled safety data for previous analyses 
described (N=12,054), the potential major adverse cardiovascu-
lar events (eg, composite of cardiovascular death, nonfatal myo-
cardial infarction, and nonfatal stroke) were assessed in patients 
randomized to receive roflumilast (Figure 5).57 Roflumilast 
was associated with a significantly lower risk of major adverse 
cardiovascular events versus placebo-treated patients: 14.3 per 
1,000 versus 22.3 per 1,000 patient-years, respectively (hazard 
ratio 0.65; 95% CI: 0.45–0.93; P=0.019).57
Table 2 Adverse reactions ($2%) associated with roflumilast 
from four 1-year placebo-controlled trials and four 6-month 
trials
Adverse 
reaction, % (n)
Roflumilast 
(n=4,438)
Placebo 
(n=4,192)
Diarrhea 9.5 (420) 2.7 (113)
Weight loss 7.5 (331) 2.1 (89)
Nausea 4.7 (209) 1.4 (60)
Back pain 3.2 (142) 2.2 (92)
Influenza 2.8 (124) 2.7 (112)
Insomnia 2.4 (105) 1.0 (41)
Decreased appetite 2.1 (91) 0.4 (15)
Notes: Reprinted by permission from Macmillan Publishers Ltd: Clin Pharmacol Ther. 
Michalski JM, Golden G, Ikari J, et al. PDE4: a novel target in the treatment of chronic 
obstructive pulmonary disease. Clin Pharmacol Ther. 2012;91(1):134–142, copyright 
2012.50
Figure 4 Changes in mean glycated hemoglobin (HbA1c) levels over 12 weeks in 
patients with newly diagnosed, treatment-naïve type 2 diabetes mellitus.
Notes: Bars represent confidence intervals. Republished with permission of the 
Endocrine Society, from Effect of the phos phodiesterase 4 inhibitor roflumilast 
on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 
diabetes mellitus. Wouters EF, Bredenbroker D, Teichmann P, et al. J Clin Endocrinol 
Metab. 2012;97(9):E1720–E1725. Copyright 2012; permission conveyed through 
Copyright Clearance Center, Inc.56
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Place in therapy
Treatment goals for patients with active COPD exacerbations 
include reducing symptoms of current exacerbations and pre-
venting further episodes. The relationship between the develop-
ment of exacerbations and disease progression and morbidity 
and mortality in patients with COPD underscores the importance 
of prevention and risk reduction. In addition, frequent exac-
erbators are a distinct clinical subgroup who are at high risk 
and need close management.10,58 For the management of stable 
COPD, guidelines generally recommend the regular use of an 
inhaled LABA and ICS, alone or in combination, for patients 
with moderate to severe COPD with recurrent exacerbations.21,22 
Additionally, preventative measures such as vaccination, 
smoking cessation, and reeducation on inhaler technique are also 
recommended. Pulmonary rehabilitation, including exercise 
training, education, psychosocial/behavioral intervention, and 
nutritional therapy, can also reduce exacerbations.21
While treatment with LABAs and ICS are associated with 
reductions in exacerbations, patients still suffer from these 
episodes over time.58 In addition, long-term ICS therapy may 
be associated with an increased risk of pneumonia. Data from 
the INSPIRE (Investigating New Standards for Prophylaxis 
in Reducing Exacerbations; NCT00361959) study indicated 
that pneumonia was more common among patients receiving 
ICS therapy, with the risk apparently related to protracted 
symptomatic exacerbations.59 One retrospective analysis of 
a patient claims database indicated an increased pneumonia 
risk of 38%, 69%, and 157% for patients taking low-dose 
(,500 µg daily), medium-dose (500–999 µg daily), and 
high-dose ($1,000 µg daily) ICS therapy, respectively.60 
There appear to be differences between ICS for the risk of 
pneumonia, with a 73% higher rate of pneumonia among 
patients receiving fluticasone/salmeterol compared with those 
receiving budesonide/formoterol.61
Roflumilast is a PDE4 inhibitor with demonstrated effi-
cacy for improving lung function and decreasing exacerba-
tions in patients with severe to very severe COPD associated 
with chronic bronchitis. This includes decreasing the inci-
dence of exacerbations in frequent exacerbators and also of 
hospitalization.31,32,34,35 Thus, roflumilast in combination with 
a LABA with or without an ICS or a long-acting muscarinic 
antagonist appears to be a reasonable alternative choice for 
patients with severe to very severe COPD associated with 
chronic bronchitis and a history of COPD exacerbations. As 
of now, the benefits of roflumilast are most well established in 
those with severe disease. A recent benefit/harm analysis of 
the use of roflumilast in patients with COPD found that only 
patients with a high risk of severe exacerbations achieved a 
net benefit from roflumilast therapy.62
Extrapulmonary manifestations of COPD also need 
to be taken into consideration when managing patients. 
Recent evidence suggests that COPD has manifestations 
beyond the respiratory tract, including an increased risk of 
cardiovascular disease, osteoporosis, diabetes, and anxiety/
depression.2,63 One of the key mechanisms underlying these 
systemic manifestations is low-grade, chronic systemic 
inflammation, and it is possible that these represent a com-
mon pathophysiology or at least shared risk factors. Data 
supporting this include the observation that roflumilast 
decreases the risk of cardiovascular events in patients with 
COPD57 and that the drug improves glucose homeostasis in 
patients with type 2 diabetes mellitus.56 Thus, the current 
target population for the use of roflumilast is patients at 
high risk who have a higher risk for exacerbations, COPD 
hospitalization, and death.64
Additional trials are underway to further define the role 
of roflumilast for targeting the underlying systemic inflam-
mation associated with COPD. Another ongoing trial (Trial 
to Assess the Anti-inflammatory Effects of Roflumilast in 
COPD; NCT01509677) is evaluating the effect of roflumi-
last 500 µg versus placebo on inflammation parameters in 
bronchial biopsy tissue specimens in patients with moderate 
to severe COPD associated with chronic bronchitis.65
In summary, clinical efficacy, quality of life, and cost-
effectiveness data suggest that roflumilast can be an important 
and cost-effective alternative to ICS in the prevention of 
exacerbations, particularly for patients with severe to very 
Figure 5 Pooled analysis of the incidence rate of the composite of MACE (nonfatal 
MI, nonfatal stroke, and CV death) for patients receiving roflumilast (n=6,563) or 
placebo (n=5,491).
Notes: Adapted with permission from the American College of Chest Physicians. 
White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving 
roflumilast for the treatment of COPD. Chest. 2013;144(3):758–765.57
Abbreviations: Cv, cardiovascular; MACe, major adverse cardiovascular events; 
MI, myocardial infarction.
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severe COPD associated with chronic bronchitis and a history 
of exacerbations.
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